Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
LPA2 and LPA3 with Ki of 0
13)/t8-/m0/s1/i1D
once daily for 21 d) protects islet from damage
Santucci Z
None of the mice have to be removed from the study because of adverse side effects of the treatment
PF-5006739 Size:Contact [email protected] for quotation LPA2 and LPA3 with KiPF 5006739 is a potent and selective inhibitor of CK1 with IC50s of 3. 9 nM and 17. 0 nM, respectively. PF 5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1 and high kinome selectivity. PF 5006739 attenuats opioid drug seeking behavior in a rodent operant reinstatement model in animals in a dose dependent manner. PF 5006739 improves glucose tolerance in both diet induced obesity
US$ 34.99
US$ 69.99
US$ 120.00
US$ 89.99
US$ 20.00
US$ 11.00